Argenx reports first quarter 2024 financial results and provides business update

$398 million in first quarter global net product sales fda review ongoing for cidp sbla with pdufa target action date of june 21, 2024 on track to submit filing for pre-filled syringe (pfs) in second quarter 2024 management to host conference call today at 2:30 pm cet (8:30 am et) may 9, 2024, 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2024 results and provided a business update. “the team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said tim van hauwermeiren, chief executive officer of argenx.
ARGX Ratings Summary
ARGX Quant Ranking